Business
BriaCell's Bria-OTS+(TM) Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing pot...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal\n\n\n\n\n\n\n Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platform\n \n\n\n\n\n\n Bria-OTS+, a novel personalized,\n \n\n\n\n off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for patients with cancer\n \n\n\n\n\n\n This study was conducted in collaboration with the NCI\n \n\n\n\n\n\n\n PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) --\n \n BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT)\n \n (“\n \n BriaCell\n \n ” or the “\n \n Company\n \n ”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the publication of the mechanism of action of its next generation personalized off-the-shelf immunotherapy. This research conducted in collaboration with the National Cancer Institute (NCI), the US federal government’s principal agency for cancer research and training, has been published at JCI Insight, a highly rated peer-reviewed journal dedicated to advancing biomedical research from preclinical discovery through to clinical development.\n \n\n Publication Title:\n \n Enhancing dendritic cell cancer vaccine by allogeneic MHC class II expression and Treg depletion (our reference 189024-INS-RG-RV-4)\n \n\n\n “These findings help us better understand the anti-tumor effects of Bria-OTS+ in cancer patients,” stated Jay A. Berzofsky, MD, PhD, Senior Investigator of NCI and coauthor of the publication. “The study demonstrated that semi-allogeneic dendritic-cell vaccines recruit alloreactive CD4⁺ T-cell help through mismatched MHC class II molecules, which in turn strengthens antigen-specific CD8⁺ T-cell responses against tumors.”\n \n\n “This publication validates the core design principle behind Bria-OTS+: partial HLA matching enables effective tumor-antigen presentation, while planned HLA mismatching drives robust CD4⁺ helper responses,” noted Miguel Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. “These findings are directly aligned with BriaCell’s pipeline of al...